Scientific publications

CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of Ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer

Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer

A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA

Phase I Results of a Phase I/II Study of Pembrolizumab and AR Signaling Inhibitor (ARSI) +/- ²²⁵Ac-J591 for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Results of combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody Ac-J591 and beta-radiolabeled ligand Lu-PSMA I&T: preclinical and initial phase 1 clinical data in patients with metastatic castration-resistant prostate cancer (mCRPC)

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC)

Phase 1 study of Ac-J591 for men with metastatic castration-resistant prostate cancer

Dose-escalation results of a phase I trial of Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC)